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Abstract 
We aimed to investigate whether the character of the immunodominant HIV-Gag peptide 
(variable or conserved) targeted by CD8+ T cells in early HIV infection would influence the 
quality and quantity of T cell responses, and whether this would affect the rate of disease 
progression. Treatment naïve HIV-infected study subjects within the OPTIONS cohort at the 
University of California, San Francisco, were monitored from an estimated 44 days post-
infection for up to six years. CD8+ T cells responses targeting HLA-matched HIV-Gag-
epitopes were identified and characterized by multi-color flow cytometry. The autologous 
HIV gag sequences were obtained. We demonstrate that patients targeting a conserved HIV-
Gag-epitope in early infection maintained their epitope-specific CD8+ T cell response 
throughout the study period. Patients targeting a variable epitope showed decreased immune 
responses over time, although there was no limitation of the functional profile, and they were 
likely to target additional variable epitopes. Maintained immune responses to conserved 
epitopes were associated with no or limited sequence evolution within the targeted epitope. 
Patients with immune responses targeting conserved epitopes had a significantly lower 
median viral load over time compared to patients with responses targeting a variable epitope 
(0.63 log10 difference). Furthermore, the rate of CD4+ T cell decline was slower for subjects 
targeting a conserved epitope (0.85% per month) compared to subjects targeting a variable 
epitope (1.85% per month). Previous studies have shown that targeting of antigens based on 
specific HLA types is associated with a better disease course. In this study we show that 
categorizing epitopes based on their variability is associated with clinical outcome. 
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Introduction 
CD8+ T cells play an important role in the control of human immunodeficiency virus type 1 
(HIV) viremia [1-4] and the immunological pressure from these cells is a major driving force 
of viral evolution [5-7]. Genetic variability is a hallmark of HIV, giving the virus the capacity 
to rapidly escape the selective pressures of the immune system [8, 9]. Changes in the peptide 
sequence can abrogate binding to the HLA-molecule and/or inhibit recognition by the T cell 
receptor (TCR). It is well known that recognition of antigen by the TCR is extremely sensitive 
[10, 11]. However, there are regions in the HIV genome that are more conserved between the 
different strains and subtypes [12]. Mutations in more conserved regions tend to have a higher 
impact on fitness and reduce the viral replication [13]. Mutations that affect viral fitness may 
in turn influence disease progression [14, 15].  
 
Several factors, both virological and immunological, are known to influence disease 
progression. The most prominent host factor associated with disease progression is the 
expression of certain HLA alleles [16-19]. Recently, several studies revealed that one of the 
most important mechanisms behind the association between HLA alleles and disease outcome 
is the character of the peptide presented by these alleles. Alleles associated with a slower 
disease progression are more prone to bind conserved epitopes [15, 20-22]. Studies show that 
Env-specific T cell responses are more frequently observed in patients with faster disease 
progression, while patients with slower progression preferentially target epitopes in the more 
conserved Gag region [23-28]. However, there are still gaps in our knowledge of how the 
level of conservation within targeted HLA class I restricted epitopes influences clinical 
outcome over time. Most observations have been reported on cross-sectional studies, focusing 
on immune responses restricted by a single HLA allele or directed against whole regions 
using overlapping peptide sets. Usually these studies have not revealed when an epitope-
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specific response is initiated, or how the quality and quantity of responses over time are 
associated with the character of the targeted peptide. This is supported by a study indicating 
that measures of the breadth and magnitude of CD8+ T cell responses at three months post-
infection cannot predict viral load and disease progression at 12 months post-infection [29]. 
Answering these questions would be valuable for the characterization of effective CD8+ T 
cell responses and design of vaccine antigens.  
 
We hypothesized that the character of the peptides targeted early in HIV infection influences 
the efficacy of T cell responses over time, where targeting of conserved epitopes would be 
associated with beneficial disease outcome. To test this hypothesis we conducted a 
longitudinal study of Gag-specific CD8+ T cell responses in HIV-infected study subjects 
monitored from primary infection [30]. We found that the character of the HIV-Gag-peptide 
targeted in early infection was associated with viral load and the CD4+ T cell count over time. 
This study shows that the character of targeted antigens in early HIV infection is an important 
determinant for the efficacy of the immune responses that may influence disease outcome.  
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Materials & Methods 
Study cohort 
Thirteen study subjects were selected from HIV subtype B infected patients enrolled and 
followed longitudinally from early infection within the OPTIONS cohort at the University of 
California, San Francisco [30] based on identified HIV-Gag-p17 and/or Gag-p24 antigen-
specific T cell responses in early infection [31]. Each study subject was followed 
longitudinally for 3 to 6 years while remaining treatment naïve (Table 1). In addition, HLA-
typing results were available for each subject. Thirteen patients fulfilled these criteria and 
were included in the study. The University of California, San Francisco (UCSF) Committee 
on Human Research approved this study and all patients provided written informed consent. 
 
Peptides and level of variability 
A total of 35 HLA class I restricted peptides located within the HIV-Gag-p17 and -p24 
regions and matched to the HLA type of each subject were used to identify HIV-specific 
immune responses over time. Twenty of the HLA class I restricted peptides had previously 
been verified to be targeted by the study subjects during early infection [31] and 15 peptides 
were added from previously identified broadly immunogenic epitopes [32]. All peptides 
consisted of 8-9 amino acid residues and were categorized as either conserved or variable.  
The level of variability within each epitope was based on the frequency of a particular amino 
acid among the HIV subtype B strains available at the HIV Molecular Immunology database 
(www.hiv.lanl.gov). The dataset contained 3869 and 3664 sequences for the Gag p17 and Gag 
p24 regions, respectively. After obtaining the genetic variability as a percentage of amino acid 
conservation of each epitope, the median and interquartile range was calculated for the set. An 
epitope was considered conserved if it belonged to the top 25 percentile (> 79.7% 
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conservation), while the rest of the epitopes were defined as variable. Peptides synthesized by 
GeneScript (Piscataway, USA) had a purity of at least 70%.  
 
Characterization of epitope-specific CD8+ T cell responses 
Identification of HIV-specific cytokine-producing cells was made using an intracellular 
cytokine staining (ICS)-assay [33]. In brief, 5 x 10
5
 PBMCs/well were plated with HLA-
matched HIV-Gag-peptides, positive control (staphylococcus enterotoxin B plus 
lipopolysaccharide), or medium alone (negative control). Brefeldin A (Sigma Aldrich) was 
added (5 g/mL) after 1 hour to each well and incubated at 37C for an additional 5 hours. 
Stimulated PBMCs were washed with FACS Buffer (PBS with 2 mM of 
ethylenediaminetetraacetic acid and 0.5% bovine serum albumin) and stained for surface 
markers with Pacific Blue-conjugated anti-CD4 antibody (clone RPA-T4), allophycocyanin 
(APC)-Cy7-conjugated CD8-APC-Cy7 (clone SK1), and aqua amine reactive dye to identify 
dead cells. The cells were permeabilized with FACS Permeabilizing Solution 2 (Becton 
Dickinson) followed by intracellular staining with phycoerythrin-Texas
 
Red (ECD)-
conjugated anti-CD3 (clone UCHT1 from Beckman Coulter), APC-conjugated anti-IFNγ 
(clone B27), phycoerythrin (PE)-conjugated anti-MIP-1β (clone D21-1351), Alexa700-
conjugated anti-TNFα (clone MAb11) and fluorescein isothiocyanate (FITC)-conjugated anti-
IL-2 (Rat anti-human, clone MQ1-17H12). All antibodies were mouse anti-human from BD 
Biosciences unless otherwise stated. The sample analysis was performed within 12 hours on a 
4-laser LSR-II flow cytometer (Becton Dickinson Biosciences). Anti–mouse or anti-rat 
immunoglobulin G–coated beads were stained separately with each fluorochrome-conjugated 
mouse or rat antibody and used for software-based compensation. Final flow cytometric 
analysis was carried out using FlowJo (TreeStar). A positive response was defined as twice 
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the negative background and at least 0.05% IFN-producing CD8+ T cells (Figure 1). All data 
are presented after subtraction of the background.  
 
HIV gag amplification and sequencing from viral RNA 
Viral RNA from 1.0 mL of ACD or EDTA blood plasma was extracted using QIAamp Viral 
RNA kits (Qiagen). The HIV gag regions (HXB2 nucleotides 737 through 2096) were 
sequenced using a nested, two-step RT-PCR procedure. In brief, HIV cDNA was generated 
from 8 µL viral RNA using Thermoscript RT combined with Superscript II (Invitrogen Life 
Technologies, San Diego, CA) and primer RA01 (5’-
CTGCTCCTGTATCTAATAGAGCTTC-3’; positions 2313-2337). A 1.6 kb amplicon was 
generated from 5.0 µL cDNA using the FastStart PCR kit (Applied Biosystems, Foster City 
CA), primers 737F (5’-GCGACTGGTGAGTACGCC-3’; positions 737-754) and RA01 
under the following conditions: 94°C x 2’, 35(94°C x 30”, 56°C x 30”, 68°C x 2‘),68°C x 
4‘,10°C hold. 1 µL of the PCR product was used for each of the three nested PCR using 
primer pairs 737F and JA155mod (5’-CTGATAATGCTGAAAACATGGGTA-3’; positions 
1295-1318); 1232F (5’- ACCTAGAACTTTAAATGCATGGG-3’; positions 1233-1255) and 
1754R (5’- CAACAAGGTTTCTGTCATCC-3’; positions 1736-1755); 1503F (5’-
GGAAGTGACATAGCAGGAA-3’; positions 1486-1504) and 2095R (5’-
TTCCCTAAAAAATTAGCCTG-3’; positions 2077-2096) using the following conditions: 
94°C x 2’, 30(94°C x 30”, 56°C x 30”, 68°C x 30’), 68°C x 4‘, 10°C hold. PCR products were 
treated with ExoSAP-IT (GE Healthcare Life Sciences) and quantified by PicoGreen 
(Invitrogen/Life Technologies). The nested PCR primers also served as the sequencing 
primers using BigDyev3 cycle sequencing chemistry (Applied Biosystems/Life Technologies). 
Amplicon sequences were determined using a 3730xl capillary array sequencer (Applied 
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Biosystems/Life Technologies). Forward and reverse sequences were analyzed and edited 
using Sequencher (v. 4.6, Genecodes, Ann Arbor MI). The sequences have been submitted to 
GenBank and received the following accession numbers: JF905572-JF905594. 
 
Statistics 
Statistical calculations and graphical presentations were performed using GraphPad Prism 5.0 
statistical software and SAS version 9.2 (SAS Institute, Cary, NC). The cytokine production 
by CD8+ T cells was illustrated using SPICE 5.1 software [34]. Differences in CD4+ T cells 
over time between groups were assessed using linear mixed models.  CD4+ T cell count was 
log transformed in all models.  The type of epitope targeted (variable or conserved) and 
follow up time were considered as covariates.  Random effects for time and intercept allowed 
for individual differences in CD4+ T cell slope and initial level.  A term for covariance 
between the two random effects did not substantially improve fit to the data and so was 
omitted from the primary model.  Comparing intercepts and slopes fitted by simple linear 
regression separately on each individual's data produced qualitatively similar results. 
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Results  
The aim of this study was to investigate the association between genetic variability within 
targeted HLA class I restricted HIV Gag epitopes, the quantity and quality of the specific 
CD8+ T cell response, and clinical predictors of disease outcome following early infection.  
The selection of patients, and their responding epitopes, was based on results from a previous 
study conducted by Streeck et al [31], where the immunodominance pattern of the first virus-
specific CD8+ T cell responses developed during primary HIV infection were obtained from 
83 study subjects within the OPTIONS cohort at the University of California, San Francisco 
[30]. From these 83 study subjects, only 13 fulfilled our inclusion criteria that consisted of the 
following: 1) identified HIV-Gag-p17 and/or Gag-p24 antigen-specific T cell responses in 
early infection, 2) longitudinal follow-up for at least three years, 3) remaining treatment naïve 
during the study period, and 4) access to available plasma and PBMC samples from three to 
four time points collected approximately one year apart during the study-period (Table 1). 
However, the results from one subject were excluded due to low cell viability at the first time 
point (< 60% live cells) and two subjects did not respond to any of the tested peptides and 
were thus excluded. Therefore, complete data sets from ten subjects were used in this study. 
The first blood sample was drawn during early infection (median: 101 days from infection; 
IQR: 76 – 120 days) with the following three to four PBMC samples collected approximately 
one year apart during the study period (median: 3.3; IQR: 2.8 – 5.2 years). The data for both 
CD4+ T cell count (median 20 times per patient) and plasma viral load (median 18 times per 
patient) were documented during the entire study-period.  
 
HIV-specific T cell responses against the panel of 35 HLA-matched optimal HIV-Gag-p17 
and -p24 peptides (mean 8 peptides/patient; range 5 - 13), including the 20 previously verified 
Gag peptides targeted by the study subjects during early infection [31], were tested using the 
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ICS assay. All time points of PBMC samples from a subject were analyzed simultaneously. 
The HIV-Gag-epitope inducing the strongest, immunodominant, CD8+ T cell response was 
confirmed at the first time-point during early infection in each subject and longitudinally 
monitored. Patients were divided into two groups based on whether the targeted Gag peptide 
was considered conserved or variable (see material and methods for details). The first 
identified HIV-Gag response in five study subjects was directed against a conserved peptide 
and the remaining five patients targeted a variable peptide. Samples were available and 
analyzed from at least three time-points for all study subjects. At the fourth time-point, 
samples were available from three patients targeting a variable epitope, and four of the 
patients targeting a conserved epitope (Table 1).   
 
Quantitative but not qualitative differences of responses targeting conserved versus variable 
peptides over time   
The quality of the responses were monitored over time as measured by the ability of the 
antigen-specific CD8+ T cells to produce IFN, MIP-1, TNF and IL-2, i.e. if they were 
polyfunctional. Since the tested peptides were optimal for binding to HLA class I recognized 
by CD8+ T cells, we did not consider any CD4+ T cell responses. There was no clear 
difference in the percentage of polyfunctionality between the patients targeting a variable 
(Figure 1A) versus conserved (Figure 1B) epitope. Instead, the percentages of polyfunctional 
and monofunctional cells remained largely unchanged over time in both groups except for a 
significant decline in the magnitude of dually IFN and MIP-1 producing CD8+ T cells 
targeting a variable epitope between the first and fourth time point (P = 0.046). Also, the 
magnitude of antigen-specific responses in patients targeting conserved peptides show 
persistently higher values for all functional combinations at the third and fourth time point 
compared to patients targeting variable epitopes.  
 Page 10 of 38
11 
 
 
When investigating each cytokine separately, a decline in the epitope-specific IFN 
production in subjects targeting a variable peptide in early infection was evident between the 
first and third time-points (mean drop 0.53, 95% CI -0.033 to 1.095, P = 0.059), and first and 
fourth time-points (mean drop 0.74, 95% CI -0.66 to 2.13, P = 0.076), although the decrease 
was not statistically significant (data not shown). In contrast, patients targeting a conserved 
peptide maintained their responses throughout the study period after a non-significant initial 
drop in the magnitude of IFN between the first and second time-point (mean drop 0.48, 95% 
CI -0.65 to 1.61, P = 0.30, data not shown). 
 
Early variable epitope responders targeted a larger total number of variable compared to 
conserved Gag epitopes over time, and maintained the functional profile  
To further test whether the functional profiles differed between CD8+ T cell responses against 
variable and conserved epitopes we compiled the results from time point one to three to 
distinguish the overall polyfunctionality. We excluded time point four as immunological data 
was lacking from three individuals at this time-point. We found that the individuals targeting 
variable epitopes generated a higher fraction of polyfunctional responses compared to the 
conserved epitopes (Figure 2A; P = 0.053), although the difference was not statistically 
significant. The detected difference was driven by a higher fraction of the variable-specific 
CD8+ T cells dually producing IFN and MIP-1 (Figure 2A; P = 0.016). When we extended 
the analysis to include responses against all tested variable and conserved peptides, including 
subdominant epitope responses, we distinguished the same tendencies where CD8+ T cell 
responses in the variable group showed a higher degree of polyfunctionality (P = 0.085, data 
not shown).  
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Next we investigated the character of all targeted epitopes in each subject at time point three. 
In the conserved group, a similar and low number of conserved and variable epitopes were 
targeted (Figure 2B, P = 1.000). Interestingly, subjects who had an early response against a 
variable epitope also targeted a larger total number of variable compared to conserved Gag 
epitopes at time point three (Figure 2C, P = 0.029). Taken together, our results show that 
although the magnitude of the responses decreases over time in patients targeting a variable 
epitope, there was no limitation of the functional profile and they were likely to target 
additional variable epitopes.  
 
Early targeting of conserved peptides was associated with lower plasma viral load and 
slower CD4+ T cell depletion 
We next investigated whether the character of the peptide inducing the immunodominant Gag 
response during early infection had an effect on the clinical outcome. Table 2 summarizes the 
CD4+ T cell count and plasma viral loads at each selected time point for both the conserved 
and variable epitope-targeting groups. At the first sampling time point, which occurred during 
early infection, there was a non-significant viral load difference (0.76 log10 difference in 
medians, P = 0.68) between the two groups (Figure 3A). At the second time point the median 
viral load in patients targeting conserved epitopes was significantly lower (0.93 log10 
difference, P = 0.012), suggesting a better control of the viral replication in these individuals. 
The enhanced viral control in the group of patients targeting a conserved epitope was 
maintained at the third time point (0.58 log10 difference, P = 0.022). At the fourth time point 
the viral load difference between the two groups were larger, but with greater uncertainty 
(1.55 log10 difference, P = 0.052), which may relate to the smaller number of patients in the 
groups at this time point (conserved: n = 3, and variable: n = 4).  
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The strongest determinant of disease outcome is the rate of CD4+ T cell decline, i.e. a 
negative CD4+ T cell slope. We found a significant correlation (r = -0.89, P = 0.001) between 
the CD4+ T cell slope and median viral load over the study period (Figure 3B). Next we 
tested whether the character of the Gag peptide targeted in early infection was associated with 
the rate of CD4+ T cell decline. We found that patients targeting variable epitopes had an 
average CD4+ T cell decline of 1.85% per month (95% CI: 0.06% to 3.61% decline) while 
patients targeting conserved epitopes had a much slower average CD4+ T cell decline of 0.85% 
per month (95% CI: 0.11% to 1.59% decline). The difference in CD4+ T cell decline between 
the groups was substantial, though it was at the border of statistical significance (P = 0.054) in 
this relatively small cohort of subjects (Figure 3C). To visualize the change in CD4+ T cell 
counts in the two groups another way, all available CD4+ T cell counts for each subject in this 
study was graphed against time enrolled in the OPTIONS cohort (Figure 3D). By fitting a 
least squares regression line, the rate of CD4+ T cell decline appears greater in subjects 
targeting variable epitopes. Although subjects targeting a variable epitope had an estimated 
37.5% higher CD4+ T cell count (CI 5.2% to 79.9%, P = 0.021) at the first time point, 
differences in fitted CD4+ T cell count were not statistically significant at any other time 
point. The more rapid loss of CD4+ T cells in the variable group appears to erode the initial 
advantage.  
 
Comparison of the autologous viral sequences with the sequence of the tested peptides 
In order to characterize how dependent the presence and preservation of the immune 
responses against conserved epitopes were to sequence identity with the tested epitope, we 
sequenced the autologous virus at time point one and three for all patients (Table 3). At time 
point one, all but one of the autologous conserved epitope sequences was identical to the 
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tested peptide. A substantially larger number of amino acid substitutions were detected within 
the variable epitopes. Already at time point one, three out of five sequenced epitopes 
contained amino acid differences compared to the tested epitopes. Over time changes were 
detected in four out of the five epitopes. Overall, these results are in agreement with the idea 
that the maintained HIV-specific CD8+ T cell responses against the conserved epitopes are 
due to the absence of, or limited and conserved, sequence changes within these epitopes.  
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Discussion 
We investigated how the genetic variability within the targeted Gag peptides in early HIV 
infection influenced the quality and quantity of the antigen-specific CD8+ T cell responses 
over time. We hypothesized that early targeting of conserved epitopes would be beneficial, as 
responses against such epitopes would maintain their antiviral effect for a longer time period. 
The study subjects were untreated and followed longitudinally for at least three years from 
early HIV infection. The analyses were restricted to responses against Gag-peptides as we 
hypothesized that the putative beneficial role of immune responses against this region [31] is 
dependent on the level of conservation of the targeted epitopes rather than the location of the 
epitope. We showed that patients targeting a variable Gag epitope in early infection continued 
to preferentially target variable epitopes over conserved epitopes, while the subjects targeting 
conserved epitopes maintained their response against the conserved epitopes throughout the 
study period. Maintenance of immune responses were associated with no or limited sequence 
evolution within the conserved epitope. Importantly, we found that patients targeting a 
conserved epitope had a slower CD4+ T cell decline and significantly lower viral load during 
the study period compared to patients targeting variable epitopes. While restricting our 
analyses to Gag epitopes likely underestimates the contribution of other antigen variable and 
conserved epitopes to mediating viral load and disease progression, our results are in 
agreement with a larger study that performed comprehensive analyses of T cell responses 
across the HIV proteome [28]. In that study, T cell responses to conserved epitopes remained 
detectable out to 12 months post-infection and were enriched in individuals maintaining lower 
viral loads [28]. Our study suggests that the type of epitope targeted in Gag during acute 
infection, conserved versus variable, sets the stage for the type of epitopes targeted during 
chronic infection. 
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HIV is a chronic infection with great variation in disease outcome among infected individuals 
(reviewed in [35]). The strongest host factor associated with a slower disease progression has 
been the expression of certain HLA-alleles in the host [36]. Recent studies have shown that 
HLA-alleles associated with better disease outcome frequently bind conserved peptides [15, 
20-22]. Binding of conserved peptides is likely to be beneficial due to the slower rate of 
mutations and because mutations, especially within structural proteins, can result in a virus 
with reduced replicative capacity (i.e. lower viral fitness) [13, 26, 27, 37]. Troyer et al showed 
that escape mutations in the conserved Gag-p24 capsid protein lead to changes in the 
secondary structure and a reduced viral fitness, while no effect or even enhanced viral fitness 
was seen when escape mutations occurred in the Env region [13]. Hence, several factors 
associated with better disease progression are based on the character of the targeted peptide. 
However, many of these studies have been cross-sectional [21-24, 38, 39]. It is therefore 
difficult to know which factors are causing the enhanced control and which are the result of a 
more intact immune system and lower antigen exposure in the slow progressors [40]. 
Furthermore, it is not clear when these beneficial responses develop, since most studies have 
been performed during chronic infection. In this study we could monitor variable and 
conserved epitope responses identified in early infection and longitudinally follow them for 
up to four years of untreated infection. In agreement with a previous longitudinal study [28], 
we show that the character of peptides targeted early in infection affected the magnitude of 
the antigen specific responses as well as several important clinical markers of disease 
outcome over time. 
 
The fact that the peptide character influenced persistence or loss in cytokine production by 
antigen-specific T cells was expected. Responses targeting conserved peptides are likely to be 
maintained longer than responses against variable peptides due to the lower rate of mutations 
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that permit immunologic escape. Escape mutations occur in early infection as well as 
continuously during chronic infection [8, 41-43]. In our study we sequenced the autologous 
virus at the first and third time point and identified amino acid substitutions within the 
targeted Gag peptide. Interestingly, several amino acid substitutions were already present at 
the initial sequencing time point in variable epitopes. While we cannot determine whether 
these mutations represent transmitted mutations or early escape, it is interesting to postulate 
that such early mutations may further drive the propensity of variable epitope responders to 
continue to target variable epitopes. Indeed, we found that subjects targeting a variable 
peptide had mutations accruing over time within this epitope, while most of the subjects 
targeting a conserved peptide had an identical peptide sequence at time point one and three. 
Thus, we could confirm that the loss of response in patients targeting a variable peptide was 
likely a result of an abrogated HLA-peptide-TCR interaction due to mutations within the 
epitope. In addition, the loss of responses was not associated with limitations in the functional 
profile. Instead, the fraction of CD8+ T cells producing IFN and MIP-1 was higher than in 
the conserved group despite the fact that the majority of their detected responses were 
directed against Gag epitopes that were characterized as variable. Unexpectedly, and despite 
the small number of participants in this study, we saw an effect on the CD4+ T cell slope and 
viral load depending on the peptide character initially targeted by the first Gag-specific CD8+ 
T cells response in the subjects. Even though patients targeting a variable epitope had a higher 
CD4+ T cell count at the initiation of this study, they also had a faster depletion of the CD4+ 
T cells in circulation. The higher CD4+ T cell count in subjects targeting a variable epitope at 
time point one could not be explained by the estimated duration of infection in months at the 
time for the first specimen, based on our estimated infection date. Thus, there must be another 
explanation for the difference in initial CD4+ T cell levels or it could be a random result due 
to the limited numbers of subjects studied. Our results indicate an important role for the initial 
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immune response to the partial control of viral replication during the first years of infection. 
Two of the study subjects targeted epitopes that were HLA-B7 restricted, which is an allele 
that has not been shown to be associated with slow progression [44]. The targeted epitope in 
these two study subjects was considered variable and the subjects belonged to the group that 
had faster CD4+ T cell decline and higher viral load over time. Our findings are also in 
agreement with our previous study showing that early viral escape is associated with the 
development of new epitope-specific T cell responses and loss of viral control in HLA-A2-
positive subjects [9]. In addition, we showed that the majority of the epitope-specific 
responses were against other variable epitopes in the variable responders during the study 
period. We found limited associations between the functional profile of the peptide responses 
and the differences in viral load and CD4+ T cell decline. Instead, our results support the 
theory that the character of the peptide bound and presented on the HLA-alleles influences 
disease progression.  
 
It is still not clear whether a T cell based vaccine should aim for induction of broad responses 
targeting several peptides or induce a strong and narrow response [9, 24]. Our study does not 
answer these questions, but supports the importance of immune responses against conserved 
epitopes in early infection, even if the numbers of targeted epitopes are limited.  However, 
CD8+ T cell responses against a conserved Gag epitope might not be more beneficial than a 
response against conserved epitopes in other regions or broader responses targeting multiple 
epitopes. Also, our study was restricted to a limited number of study subjects why the lack of 
significance for some of the comparisons might be due to lack of statistical power. Despite 
these limitations our results show that the level of conservation of epitopes targeted by the 
initial HIV-Gag-specific CD8+ T cell responses is a factor that by itself is a predictor for 
 Page 18 of 38
19 
 
disease outcome (i.e. viral load and CD4+ T cell count) that should be carefully considered in 
T cell based vaccine development.  
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Figure legends 
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Figure 1. Sustained magnitude of CD8+ T cell responses against conserved epitopes.  
Polyfunctional responses were measured by detection of IFN, IL-2, MIP-1, and TNF 
production at T1 to T4. The distribution of polyfunctional CD8+ T cells is illustrated in the 
pie charts for variable (A) and conserved (B) responders, showing the ratio of T cells 
producing one, two, or three cytokines upon antigen stimulation in different colors. In the 
column-chart the magnitude of antigen-specific CD8+ T cells with a particular functionality is 
visualized at the four time points in different shades of gray. P-values were calculated in 
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SPICE using the student s´ T test and permutation tests. Samples were available and analyzed 
from three time-points for all study subjects. At the fourth time-point, samples were available 
from three patients targeting a variable epitope, and four of the patients targeting a conserved 
epitope. 
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Figure 2. Early targeting of a variable Gag-epitope associated with IFN and MIP-1 
producing CD8+ T cells.  
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The functional distribution of all detected Gag-specific CD8+ T cell responses at T1 to T3 is 
illustrated in the pie chart and column chart in subjects with early targeting of a variable or 
conserved epitope (A). P-values were calculated in SPICE using the student s´ T test and 
permutation tests. The total number of targeted epitopes characterized as variable and 
conserved at time point three in the subjects grouped as conserved (B) and variable (C) 
responders in early infection (mean and SEM indicated). P-values from pair t-test (two-tailed). 
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Figure 3. Targeting of a conserved epitopes associated with lower viremia and slower 
CD4+ T cell depletion. The median and interquartile ranges of viral load (copies/ml) in 
patients with early targeting of conserved and variable epitopes are illustrated at time point 
one to four (A). P-values from a Mann-Whitney test of viral loads are given. From the last 
time point (T4) fewer samples were available, three from subjects targeting variable epitope 
and four from subjects in the conserved group.  A clear correlation is seen between the 
median viral load and the CD4+ T cell slope over time, calculated using Spearman s´ rank test 
(two-tailed) (B). The median CD4+ T cell slope in patients targeting conserved epitopes 
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compared to study subjects targeting a variable epitope (C). P-value from Mann-Whitney test 
is given. Scatter plot showing absolute CD4+ T cell numbers over time (months since first 
OPTIONS visit), with least squares fitted lines.  Blue dots and red line indicate patients 
targeting variable epitopes, and the green dots and orange line indicate patients targeting 
conserved epitopes (D). Time point one to four: T1 to T4. 
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Table 1. Clinical, virological and immunological characteristics 
Patient 
ID 
HLA 
class I A 
HLA 
class I B 
CD4+ 
T cell 
Range 
(cells/mm
3
) 
1 
CD4+ 
T cell 
slope
2 
Viral load 
range
1 
(log10) 
Viral load 
median
 
(log10) 
Estimated 
time since 
infection 
(month) 
Study 
period 
(month) 
Peptide 
character
3 
Protein 
region
4 
Peptide 
sequence
5 
OP562 A1, A3 B35, B51 378-1152 -7,93 3.60-5.58 4.45 3 65 Variable Gag p17 RLRPGGKKK 
OP565 A1, A24 B8, B50 288-650 -3,79 3.75-5.20 4.43 7 34 Conserved Gag p24 EIYKRWII 
OP584 A3, A30 B44, B51 328-760 -5,80 2.74-4.97 4.25 4 56 Conserved Gag p17 EEKAFSPEV 
OP639 A2, A3 B7, B27 480-1155 -4,66 3.39-5.30 4.39 5 73 Variable Gag p24 GPGHKARVL 
OP653 A25, A68 B7, B35 506-1404 -20,91 3.96-4.88 4.65 15 34 Variable Gag p24 GPGHKARVL 
OP722 A3, A11 B7, B40/60 132-616 -11,76 4.71-5.23 5.16 3 30 Variable Gag p17 RLRPGGKKK 
OP781 A2, A25 B44, B44 267-759 -6,99 4.01-4.91 4.44 3 34 Conserved Gag p24 ETINEEAAEW 
OP835 A1, A30 B8, B39 420-1060 1,42 2.08-3.92 2.74 4 62 Conserved Gag p24 TPQDLNTML 
OP842 A3, A25 B40/60, 55 319-633 -8,56 3.77-5.07 4.57 2 29 Variable Gag p17 RLRPGGKKK 
OP849 A1, A2 B7, B8 320-555 -3,88 2.30-4.06 3.63 5 39 Conserved Gag p24 EIYKRWII 
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1
The highest and lowest CD4 or viral load measurements detected in the samples obtained during the study-period, before initiation of treatment. 
2
CD4+ T cell slope (cells/mm3) calculated from all available measurements during the study-period, before initiation of treatment. 
3
Peptide characteristics of immunodominant peptide identified in early infection 
4
Location of the peptide targeted by the initial immunodominant CD8+ T cell response in early HIV-1 infection. 
5
Amino acid sequence of the peptide targeted by the initial immunodominant CD8+ T cell response in early HIV-1 infection. 
 Page 35 of 38 
36 
 
 
Table 1. Clinical, virological and immunological characteristics 
  
 Page 36 of 38
37 
 
Table 2. Summary measures of CD4+ T cell counts and plasma viral loads at selected time points. 
 
  Median (IQR) Mean (SD) 
Laboratory 
Test 
Time point Variable  epitope Conserved epitope Variable epitope Conserved epitope 
CD4 Time 1 930 (546-990) 532 (504-684) 795 (258) 574 (123) 
 Time 2 621 (445-756) 486 (476-578) 636 (205) 586 (210) 
 Time 3 637 (359-644) 428 (420-546) 491 (238) 463 (101) 
 Time 4 480 (378-607) 362 (302-557) 488 (115) 429 (186) 
      
Viral load Time 1 4.48 (4.31-4.88) 3.76 (3.42-4.60) 4.41 (0.63) 3.94 (0.91) 
(Log10) Time 2 4.98 (4.76-5.07) 4.05 (3.95-4.28) 4.89 (0.29) 3.89 (0.61) 
 Time 3 4.59 (4.46-4.71) 4.01 (2.95-4.22) 4.55 (0.20) 3.57 (0.91) 
 Time 4 5.30 (4.65-5.31) 3.75 (2.97-4.51) 5.09 (0.38) 3.74 (0.89) 
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Table 3 
The autologous sequences of the identified immunodominant peptide in early infection at time point one and 
three. 
Patient ID Tested peptide 
sequence1 
Level of 
variability 
T1 date T1 sequence2 T3 date T3 sequence3 Peptide 
character4 
OP565 EIYKRWII 82.8 Dec 2000 --------- Oct 2003 --------- Conserved 
OP584 EEKAFSPEV 89.5 Apr 2001 --------- Sept 2005 --------- Conserved 
OP849 EIYKRWII 82.8 Apr 2004 ----K---- Jul 2006 -V--K---- Conserved 
OP781 ETINEEAAEW 87.7 Aug 2002 --------- Aug 2005 --------- Conserved 
OP835 TPQDLNTML 94.4 Apr 2003 --------- Nov 2007 NA Conserved 
OP562 RLRPGGKKK 57.8 Feb 2002 --------- May 2006 ------X-X 
      - - 
      N R 
      R   
      S 
Variable 
OP639 GPGHKARVL 68.0 Jul 2001 --S------ Aug 2007 --------- Variable 
OP653 GPGHKARVL 68.0 Oct 2001 --X---K-- 
  - 
  S 
Jun 2004 --------- Variable 
OP722 RLRPGGKKK 57.8 Mar 2003 --------X 
        - 
        R 
Aug 2004 ------X-R 
      - 
      N 
      R 
      S 
Variable 
OP842 RLRPGGKKK 57.8 Apr 2003 --------- Aug 2005 --------- Variable 
1Sequence of the tested peptide that induced the immunodominant response identified in early infection by population based 
sequencing. 2Sequence of the autologous epitope at time point one. A dash indicates identity with the tested peptide, and an X 
indicate a polymorphic position that could encode more than one amino acid (identical with the tested peptide or any of the 
other amino acids given for the autologous sequence). 3Sequence of the autologous epitope at time point three. A dash 
indicates identity with the tested peptide, and an X indicate a polymorphic position that could encode more than one amino 
acid (identical with the tested peptide or any of the other amino acids given for the autologous sequence at time point three). 
4Peptide characteristics of immunodominant peptide identified in early infection. T1: time point one; T3: time point three. 
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